Ulcerative Colitis: Optimizing Treatment Strategies to Improve Patient Outcomes - Baltimore

Gastroenterology
Curriculum:
Ulcerative Colitis: Optimizing Treatment Strategies to Improve Patient Outcomes
Credits:
2 AMA PRA Category 1 Credit(s)™
Launch Date:
May 18, 2013
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

physicians, nurses and other healthcare professionals who manage patients with Ulcerative Colitis (UC)

Relevant Terms:

Ulcerative Colitis, IBD, Non-Responsive UC, Refractory UC, Long-term Therapy, Remission

William J. Sandborn, MD, Program Chair  

William J. Sandborn, MD, Program Chair Chief, Division of Gastroenterology
Professor of Medicine
UC San Diego School of Medicine
San Diego, CA


Dr. William Sandborn completed medical school and an internal medicine residency at Loma Linda University in Loma Linda California.  He completed a gastroenterology fellowship at the Mayo Clinic in Rochester Minnesota in 1993.  From 1993-2010, he was on the faculty of the Mayo Clinic, rising to Professor of Medicine, Vice Chairman of the Division of Gastroenterology and Hepatology, and Associate Dean of Research for Intellectual Property and Industry Relations.  In 2011 he became Professor of Clinical Medicine at the University of California San Diego and Director of the IBD Center and Chief of the Division of Gastroenterology for the UC San Diego Health System.  Dr Sandborn has published over 443 peer reviewed articles including articles in the New England Journal of Medicine, the Lancet, JAMA, the Annals of Internal Medicine, and Gastroenterology.  His research interests are clinical trials and clinical pharmacology related to inflammatory bowel disease.

Marla C. Dubinsky, MD

Marla C. Dubinsky, MD
Director, Pediatric Inflammatory Bowel Disease Program
Abe and Claire Levine Chair in Pediatric Inflammatory
Bowel Disease
Associate Professor of Pediatrics
Cedars-Sinai Medical Center
Los Angeles, CA


Marla C. Dubinsky, MD is Director of the Pediatric Inflammatory Bowel Disease Program and Associate Professor of pediatrics at Cedars-Sinai Medical Center. She holds the Abe and Claire Levine Chair in Pediatric Inflammatory Bowel Disease.
 
Dr. Dubinsky's research interests include the immune and genetic influences on the natural history and treatment of inflammatory bowel disease (IBD) as well as therapeutic drug monitoring.  Her research is funded by the National Institutes of Health.

Dr. Dubinsky has lectured internationally and has also authored book chapters for Trends in Inflammatory Bowel Disease Therapy and Inflammatory Bowel Disease: Diagnosis and Therapeutics. She has also written articles for numerous peer reviewed journals including Gastroenterology, the Journal of Pediatric Gastroenterology and Nutrition, Inflammatory Bowel Diseases, and the American Journal of Gastroenterology.

Brian G. Feagan, MD

Brian G. Feagan, MD
Professor of Medicine

Departments of Medicine and Epidemiology/Biostatistics
Schulich School of Medicine
Western University
London, ON


Brian G. Feagan completed a medical degree at the University of Western Ontario in London, Ontario, Canada.  His postdoctoral training included residency in the Department of Medicine and a fellowship in Gastroenterology at the University of Western Ontario.

A Fellow of  the Royal College of Physicians and Surgeons of Canada, Dr Feagan holds membership in the Canadian and American Association of Gastroenterology, the American College of Gastroenterology, the College of Physiciaans and Surgeons of Ontario and the Crohn's and Colitis Foundation of Canada (CCFC).  He has authored over 150 articles, book chapters and has also given over 700 invited presentations, and national and international scientific meettings.  

In 1997, Dr. Feagan became Director of Robarts Clinical Trials at the Robarts Research Institute, University of Western Ontario.  His research efforts focus on the design and implementation of randomized controlled trials of therapy for inflammatory bowel disease.  He has been the principal investigator on numerous large-scale randomized clinical trials.
1. Describe the efficacy and safety data for existing, new and emerging treatments for UC
2. Appropriately select treatments for patients with UC that maximize the opportunity to achieve remission, avoid relapse and minimize complications in accordance with existing guidelines
3. Implement evidence-based strategies to improve management of therapeutic non-response or refractoriness in UC

Accreditation Statement and Credit Designation
The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.                                           
 
The AGA Institute designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
 
How to Receive Credit
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 2.0 AMA PRA Category 1 Credits™.  You must complete the post-test and evaluation in order to receive credit for this activity. 
 
All other participants who successfully complete the post-test and evaluation will receive a certificate of completion.
 
A statement of credit will be e-mailed to you and will also be available to print from your user history page. 
 
Disclosure of Conflicts of Interest
In accordance with the ACCME's Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.
 
Faculty Disclosures
William J. Sandborn, MD, has affiliations with Janssen, Abbott Laboratories (now Abbvie), UCB Pharma, Salix, Shire, Warner Chilcott, Prometheus Laboratories, Santarus, Bristol-Myers Squibb, Genentech, Amgen, Pfizer, Receptos, GlaxoSmithKline and Millennium (a Takeda company) (Consulting); Abbvie (Speakers Bureau); and Janssen, Bristol-Myers Squibb, Genentech, Amgen, Pfizer, Receptos and GlaxoSmithKline (Research).
 
Marla C. Dubinsky, MD, has affiliations with Janssen, Pfizer, Bristol-Myers Squibb, UCB, Abbott, Shire, Prometheus and Takeda (Consulting); and Janssen (Research).
 
Brian G. Feagan, MD, has affiliations with Abbott, ActoGeniX, Bristol-Myers Squibb, Centocor, CombinatoRx, Elan/Biogen, Genentech, Merck, Millennium, Novartis, Protein Design Labs, Tillotts, UCB Pharma and Wyeth (Grant/Research); Abbott (AbbVie), ActoGeniX, Albireo Pharma, Amgen, AstraZeneca, Athersys, Avaxia Biologics Inc., Axcan, Boehringer-Ingelheim France, Bristol-Myers Squibb, Celgene, Centocor, Elan/Biogen, Ferring Pharma A/S, Genentech, GiCare Pharma, Gilead, Given Imaging Inc., GSK, Ironwood Pharma, J&J/Janssen, Merck, Millennium, Nektar, Novo Nordisk, Prometheus Therapeutics and Diagnostics, Pfizer, Salix Pharma, Serono, Shire, Sigmoid Pharma, Synergy Pharma Inc., Takeda, Teva Pharma, Tillotts, UCB Pharma, Unity Pharmaceuticals, Warner-Chilcott, Wyeth, Zealand Pharm and Zyngenia (Consulting); Abbott, J&J/Janssen and UCB Pharma (Speakers Bureau); and Abbott, AstraZeneca, Celgene, Centocor Inc., Elan/Biogen, Merck, Novartis, Pfizer, Prometheus Laboratories, Salix Pharma, Takeda, Tillotts Pharma AG and UCB Pharma (Advisory Board).  

Other Disclosures
Program planners reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
 
RMEI, LLC
Jacqui Brooks, MBBCh, MRCPsych
, has no affiliations with commercial interests to disclose. 
Cynthia M. Kunzer has no affiliations with commercial interests to disclose.
 
General Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information and comparison with recommendations of other authorities.
 
Commercial Support
This is a program of the AGA Institute in collaboration with RMEI, LLC.  RMEI gratefully acknowledges an educational grant from Takeda Pharmaceuticals International, Inc., US Region in support of this CME activity.
 
Fee Information
There is no fee for this educational activity.